Last reviewed 2026-04-22 · How we verify

Bortezomib/Lenalidomide/ Low dose Dex

This combination therapy targets multiple pathways in multiple myeloma by inhibiting proteasome degradation, enhancing immune response, and reducing tumor cell survival.

This combination therapy targets multiple pathways in multiple myeloma by inhibiting proteasome degradation, enhancing immune response, and reducing tumor cell survival. Used for Multiple myeloma (newly diagnosed and relapsed/refractory).

At a glance

Mechanism of action

Bortezomib is a proteasome inhibitor that blocks NF-κB signaling and induces apoptosis in myeloma cells. Lenalidomide is an immunomodulatory drug (IMiD) that enhances T-cell proliferation and NK cell activity while also having direct anti-proliferative effects. Low-dose dexamethasone provides additional anti-inflammatory and anti-myeloma activity, and the combination has synergistic effects in suppressing multiple myeloma cell growth.

Approved indications

• Multiple myeloma (newly diagnosed and relapsed/refractory)

Common side effects

• Peripheral neuropathy
• Thrombocytopenia
• Anemia
• Neutropenia
• Nausea/vomiting
• Diarrhea
• Fatigue
• Infection
• Hyperglycemia

Key clinical trials

• Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma (PHASE3)
• Selinexor and Backbone Treatments of Multiple Myeloma Patients (PHASE1, PHASE2)
• Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (PHASE3)
• Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma (PHASE2)
• Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.